
In a study that investigated the impact of siponimod treatment on active secondary progressive multiple sclerosis (aSPMS), 46 patients were monitored over 24 months, alongside 14 healthy controls. Initially, aSPMS patients exhibited elevated levels of naïve regulatory T lymphocytes compared to controls. However, a decline in various lymphocyte subpopulations was observed throughout treatment, notably T CD4+, B lymphocytes, memory regulatory B cells, and CD3+CD20+ lymphocytes. Notably, patients without disability progression displayed a more significant reduction in B and CD3+CD20+ lymphocytes compared to those experiencing progression. These findings suggest siponimod treatment may modulate specific lymphocyte populations, with potential implications for disease progression in aSPMS.
Like
Save
Share